HUTCHMED (China) Limited (HCM)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Other Ventures	262.97M	266.84M	309.38M	262.57M	236.52M
Oncology/Immunology - Marketed Products	214.36M	271.53M	164.17M	124.64M	-
Oncology/Immunology - R&D	71.18M	91.83M	364.45M	39.20M	-
Oncology/Immunology - R&D - PRC	-	-	-	-	43.18M
Oncology/Immunology - Marketed Products - PRC	-	-	-	-	76.43M
Total	548.51M	630.20M	838.00M	426.41M	356.13M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)	407.45M	452.41M	484.90M	426.41M	-
U.S. and Others	141.06M	177.79M	353.10M	-	-
Total	548.51M	630.20M	838.00M	426.41M	-

Data Source: S&P Global Market Intelligence Last updated: Mar 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 30, 2026

Data Sources Report a data error